FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic...

34

Transcript of FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic...

Page 1: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 2: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 3: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 4: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 5: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 6: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 7: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 8: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 9: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 10: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 11: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 12: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 13: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 14: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 15: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 16: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 17: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 18: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 19: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 20: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 21: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 22: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 23: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 24: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 25: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 26: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 27: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 28: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 29: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 30: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 31: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 32: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 33: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,
Page 34: FDA-2010-P-0549-0001 · 2013. 6. 3. · Lupin, and not Teva, is eligible for 180-day generic exclusivity, pursuant to 21 U.S.C. § 355G)(5)(B)(iv), for lamivudine and zidovudine tablets,

Adverse Neuropsychiatric Events and Recreational Use of ...pharmrev.aspetjournals.org/content/pharmrev/70/3/684.full.pdflamivudine-abacavir, zidovudine-lamivudine-efavirenz, or zidovudine-lamivudine-abacavir-efavirenz.

Adverse Neuropsychiatric Events and Recreational Use of ...pharmrev.aspetjournals.org/content/pharmrev/70/3/684.full.pdflamivudine-abacavir, zidovudine-lamivudine-efavirenz, or zidovudine-lamivudine-abacavir-efavirenz.

Boyesen og Munthe - FD 10 · 2020. 3. 18. · FD 10 0549-990-01---10a_2019.11.indd! 0549-990/02a Page 4 of 69 Mounting and operating instructions 1 GENERAL REMARKS The present instructions

Boyesen og Munthe - FD 10 · 2020. 3. 18. · FD 10 0549-990-01---10a_2019.11.indd! 0549-990/02a Page 4 of 69 Mounting and operating instructions 1 GENERAL REMARKS The present instructions

Maximum tolerable doses of intravenous zidovudine in combination ...

Maximum tolerable doses of intravenous zidovudine in combination ...

MICRA M - robopac.com · ROBOPAC S.P.A. Via Fabrizio da Montebello, 81 - 47892 Acquaviva Gualdicciolo - Repubblica di San Marino - tel. + 378 0549 910 511 - fax + 378 0549 908 549

MICRA M - robopac.com · ROBOPAC S.P.A. Via Fabrizio da Montebello, 81 - 47892 Acquaviva Gualdicciolo - Repubblica di San Marino - tel. + 378 0549 910 511 - fax + 378 0549 908 549

NTCM-G 2009 en 0549 B - KCB RPV safety assessment 60 years · NTCM-G 2009 en 0549 B - KCB RPV safety assessment 60 years.doc List of revisions Rev. Date Scope of revision Reason Section/Page

NTCM-G 2009 en 0549 B - KCB RPV safety assessment 60 years · NTCM-G 2009 en 0549 B - KCB RPV safety assessment 60 years.doc List of revisions Rev. Date Scope of revision Reason Section/Page

Short-course Zidovudine Compared to What? › globalhealth › healthprotection › ... · Research Ethics Target audience: Residents in Field Epidemiology Training Programs (FETPs),

Short-course Zidovudine Compared to What? › globalhealth › healthprotection › ... · Research Ethics Target audience: Residents in Field Epidemiology Training Programs (FETPs),

REPUBLIC OF SAN MARINO CIVIL AVIATION … SM 55 _ Formal Application...REPUBLIC OF SAN MARINO CIVIL AVIATION AUTHORITY TEL: +378 (0549) 941539| FAX: +378 (0549) 970525| EMAIL: registration@smar.aero

REPUBLIC OF SAN MARINO CIVIL AVIATION … SM 55 _ Formal Application...REPUBLIC OF SAN MARINO CIVIL AVIATION AUTHORITY TEL: +378 (0549) 941539| FAX: +378 (0549) 970525| EMAIL: [email protected]

Women refusing 3 medications should be offered zidovudine prophylaxis, never Combivir alone.

Women refusing 3 medications should be offered zidovudine prophylaxis, never Combivir alone.

Zidovudine, abacavir and lamivudine increase the ...

Zidovudine, abacavir and lamivudine increase the ...

Structural Basis for HIV-1 Reverse Transcriptase Drug Resistance to Zidovudine (AZT) and Tenofovir Kalyan Das CABM & Rutgers University, NJ, USA.

Structural Basis for HIV-1 Reverse Transcriptase Drug Resistance to Zidovudine (AZT) and Tenofovir Kalyan Das CABM & Rutgers University, NJ, USA.

ISSN 0549-799X Number 359 September–October 2007

ISSN 0549-799X Number 359 September–October 2007

N QOD: National Neurosurgery Quality and Outcomes Database · • Contact NeuroPointAlliance • Info@neuropoint.org • (847) 378‐0549 • Visit Website • • Projects > Quality

N QOD: National Neurosurgery Quality and Outcomes Database · • Contact NeuroPointAlliance • [email protected] • (847) 378‐0549 • Visit Website • • Projects > Quality

FORMULATION AND IN VITRO EVALUATION OF ZIDOVUDINE MICROSPHERES

FORMULATION AND IN VITRO EVALUATION OF ZIDOVUDINE MICROSPHERES

Evaluation of the Activity of Lamivudine and Zidovudine ...

Evaluation of the Activity of Lamivudine and Zidovudine ...

FORMULATION AND EVALUATION OF ZIDOVUDINE LOADED …

FORMULATION AND EVALUATION OF ZIDOVUDINE LOADED …

Simultaneous Quantification of Lamivudine, Zidovudine and ...

Simultaneous Quantification of Lamivudine, Zidovudine and ...

zidovudine hplc method

zidovudine hplc method

- They come in all sizes. -- General Structure is similar.tmedweb.tulane.edu/.../exe/fetch.php/mondalanti-viral_drugs_f09.pdf · Drug Interactions: Probenecid and Zidovudine. •

- They come in all sizes. -- General Structure is similar.tmedweb.tulane.edu/.../exe/fetch.php/mondalanti-viral_drugs_f09.pdf · Drug Interactions: Probenecid and Zidovudine. •

ETS 42 · 2020. 2. 3. · 0549-991-41---50a_2019.11.indd ETS 42 0549-991/42a Page 4 of 18 Operator manual 2 SAFETY 2.1 Appropriate use The swing door drive mechanism ETS 42 has been

ETS 42 · 2020. 2. 3. · 0549-991-41---50a_2019.11.indd ETS 42 0549-991/42a Page 4 of 18 Operator manual 2 SAFETY 2.1 Appropriate use The swing door drive mechanism ETS 42 has been

Zidovudine Exposure during Pregnancy and …Central Clinical Research in HIV/ AIDS Cite this article: Albano JD, Sinclair S, Scheuerle AE, Watts DH, Koram N, et al. (2017) Zidovudine

Zidovudine Exposure during Pregnancy and …Central Clinical Research in HIV/ AIDS Cite this article: Albano JD, Sinclair S, Scheuerle AE, Watts DH, Koram N, et al. (2017) Zidovudine